Pharmaphorum
Servier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise’s muscular dystrophy business headed by sevasemten.
Pharmaphorum
Servier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise's muscular dystrophy business headed by sevasemten.
Pharmaphorum
Servier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise’s muscular dystrophy business headed by sevasemten.